MENU
+Compare
FMED
ETF ticker: NASDAQ
AS OF
Jan 14, 04:22 PM (EDT)
Price
$27.51
Change
+$0.26 (+0.95%)
Net Assets
63.47M

FMED stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
FMED
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for FMED with price predictions
Jan 13, 2026

FMED's Indicator enters downward trend

The Aroon Indicator for FMED entered a downward trend on January 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 73 similar instances where the Aroon Indicator formed such a pattern. In of the 73 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 32 cases where FMED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on January 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FMED as a result. In of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

FMED moved below its 50-day moving average on January 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FMED crossed bearishly below the 50-day moving average on January 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FMED broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for FMED just turned positive on January 07, 2026. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in of 26 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in of 158 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Exact Sciences Corp (NASDAQ:EXAS), Align Technology (NASDAQ:ALGN).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 42.99B. The market cap for tickers in the group ranges from 393.85M to 964.11B. LLY holds the highest valuation in this group at 964.11B. The lowest valued company is AGL at 393.85M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 54%. For the same ETF, the average monthly price growth was 151%, and the average quarterly price growth was 337%. MLTX experienced the highest price growth at 53%, while IRTC experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was -14%. For the same stocks of the ETF, the average monthly volume growth was 1% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 68
Price Growth Rating: 48
SMR Rating: 79
Profit Risk Rating: 83
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
FMED
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
82 Devonshire StreetBoston
Phone
N/A
Web
www.institutional.fidelity.com